Paper17513814
Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer.
Eckardt JR and 9 others. J Clin Oncol, 2007. Cited by 288 papers, by iCite.
Cite this record
ConductScience Library. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. Papers, record 17513814. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17513814
- Disease
- small cell lung carcinoma367 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Carcinoma, Small Cell | Major topic |
| Liver Neoplasms | Major topic |
| Lung Neoplasms | Major topic |
| Topotecan | Major topic |
| Administration, Oral | |
| Adult | |
| Aged | |
| Aged, 80 and over | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Salvage Therapy | |
| Survival Rate |
Source PubMed
Trials3
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT00003917 | Topotecan in Treating Patients With Relapsed Small Cell Lung Cancer | Results | ClinicalTrials.gov | |
| NCT02963090 | Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer | Background | ClinicalTrials.gov | |
| NCT02980809 | Topotecan Plus Apatinib Versus Topotecan Alone as Second-line Therapy in Small-cell Lung Cancer | Background | ClinicalTrials.gov |
Cited by154
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 288 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42908912 | Antibody-drug conjugates in advanced small-cell lung cancer: a systematic review and single-arm meta-analysis of later-line monotherapy. | Front Immunol | 2026 | https://conductscience.org/library/papers/42908912 | PubMed |
| 42840183 | The Five-Decade Journey of Small Cell Lung Cancer. | Cancer Commun (Lond) | 2026 | https://conductscience.org/library/papers/42840183 | PubMed |
| 42818024 | Topotecan Synergizes with SP141 in the Management of Uveal Melanoma. | bioRxiv | 2026 | https://conductscience.org/library/papers/42818024 | PubMed |
| 42523863 | Immunotherapy and the novel therapeutic development for small-cell lung cancer. | Ther Adv Med Oncol | 2026 | https://conductscience.org/library/papers/42523863 | PubMed |
| 42367288 | Efficacy and safety of nab-paclitaxel in advanced or recurrent small cell lung cancer: a single-arm meta-analysis. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42367288 | PubMed |
| 42174384 | Real-World Data of Second-Line Amrubicin Monotherapy in Patients With Extensive-Stage Small Cell Lung Cancer Who Received First-Line Chemoimmunotherapy or Chemotherapy: A Multicenter Retrospective Study. | Cancer Med | 2026 | https://conductscience.org/library/papers/42174384 | PubMed |
| 41562777 | Updates on Antibody Drug Conjugates and Bispecific T-Cell Engagers in SCLC. | Antibodies (Basel) | 2026 | https://conductscience.org/library/papers/41562777 | PubMed |
| 41383089 | Extended Follow-Up Analysis of First-Line Atezolizumab in Extensive-Stage Small Cell Lung Cancer: A Real-World Multicenter Prospective Cohort Study. | Thorac Cancer | 2025 | https://conductscience.org/library/papers/41383089 | PubMed |
| 41234559 | Doxorubicin paclitaxel in pretreated advanced small-cell lung cancer: a large real-life retrospective study. | Transl Lung Cancer Res | 2025 | https://conductscience.org/library/papers/41234559 | PubMed |
| 41222788 | Real-World Treatment Patterns and Clinical Outcomes in Patients With Extensive-Stage Small Cell Lung Cancer Treated With First-Line Platinum-Based Chemotherapy and ≥ 2 Subsequent Lines of Therapy in the United States. | Adv Ther | 2026 | https://conductscience.org/library/papers/41222788 | PubMed |
| 41189556 | Place in therapy of key treatments for platinum-sensitive, relapsed, extensive-stage small cell lung cancer with a focus on lurbinectedin: a narrative review with case studies. | Drugs Context | 2025 | https://conductscience.org/library/papers/41189556 | PubMed |
| 41181839 | Efficacy and safety of tislelizumab plus anlotinib and irinotecan as second-line treatment for extensive-stage small cell lung cancer: a single-arm, open-label, phase II trial. | EClinicalMedicine | 2025 | https://conductscience.org/library/papers/41181839 | PubMed |
| 41055143 | IDeate-Lung02: a Phase 3 study of second-line ifinatamab deruxtecan in patients with relapsed small cell lung cancer. | Future Oncol | 2025 | https://conductscience.org/library/papers/41055143 | PubMed |
| 40964483 | State of the art in treatment of small cell lung cancer. | Ther Adv Med Oncol | 2025 | https://conductscience.org/library/papers/40964483 | PubMed |
| 40866909 | Real-world evidence on the survival benefit of immune checkpoint inhibitors in combination with cytotoxic chemotherapy for patients with extensive-disease small-cell lung cancer: the Tokushukai Real World Data Project (TREAD) 06. | BMC Cancer | 2025 | https://conductscience.org/library/papers/40866909 | PubMed |
| 40596985 | Efficacy of PD-(L)1 inhibitors plus anlotinib in the second-line treatment of extensive-stage small cell lung cancer. | BMC Cancer | 2025 | https://conductscience.org/library/papers/40596985 | PubMed |
| 40583736 | Significance of Platinum-Based Chemotherapy With Programmed Death-1 Blockade in Limited Disease Small Cell Lung Cancer: A Retrospective Study. | Thorac Cancer | 2025 | https://conductscience.org/library/papers/40583736 | PubMed |
| 40240495 | Efficacy analysis and prognostic factors of first-line chemotherapy combined with immunotherapy in extensive-stage small cell lung cancer: a real-world study. | Sci Rep | 2025 | https://conductscience.org/library/papers/40240495 | PubMed |
| 40082695 | A B7H3-targeting antibody-drug conjugate in advanced solid tumors: a phase 1/1b trial. | Nat Med | 2025 | https://conductscience.org/library/papers/40082695 | PubMed |
| 39897044 | Advancement Opportunities and Endeavor of Innovative Targeted Therapies for Small Cell Lung Cancer. | Int J Biol Sci | 2025 | https://conductscience.org/library/papers/39897044 | PubMed |
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| TOPOTECAN HYDROCHLORIDE | CHEMBL1607 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL1607 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- References
- Genes
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/17513814
GET https://conductscience.org/api/papers/v1/17513814/cited_by?page=2